3j6u Citations

A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins.

OpenAccess logo Nat Commun 6 6341 (2015)
Related entries: 3j6s, 3j6t

Cited: 134 times
EuropePMC logo PMID: 25698059

Abstract

Dengue virus (DENV) infects ~400 million people annually. There is no licensed vaccine or therapeutic drug. Only a small fraction of the total DENV-specific antibodies in a naturally occurring dengue infection consists of highly neutralizing antibodies. Here we show that the DENV-specific human monoclonal antibody 5J7 is exceptionally potent, neutralizing 50% of virus at nanogram-range antibody concentration. The 9 Å resolution cryo-electron microscopy structure of the Fab 5J7-DENV complex shows that a single Fab molecule binds across three envelope proteins and engages three functionally important domains, each from a different envelope protein. These domains are critical for receptor binding and fusion to the endosomal membrane. The ability to bind to multiple domains allows the antibody to fully coat the virus surface with only 60 copies of Fab, that is, half the amount compared with other potent antibodies. Our study reveals a highly efficient and unusual mechanism of molecular recognition by an antibody.

Reviews - 3j6u mentioned but not cited (2)

Articles - 3j6u mentioned but not cited (9)



Reviews citing this publication (49)

  1. New insights into the immunopathology and control of dengue virus infection. Screaton G, Mongkolsapaya J, Yacoub S, Roberts C. Nat. Rev. Immunol. 15 745-759 (2015)
  2. Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control. Diamond MS, Pierson TC. Cell 162 488-492 (2015)
  3. Zika Virus: Immunity and Vaccine Development. Pierson TC, Graham BS. Cell 167 625-631 (2016)
  4. Dengue: knowledge gaps, unmet needs, and research priorities. Katzelnick LC, Coloma J, Harris E. Lancet Infect Dis 17 e88-e100 (2017)
  5. Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology. Priyamvada L, Hudson W, Ahmed R, Wrammert J. Emerg Microbes Infect 6 e33 (2017)
  6. Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host. Kuhn RJ, Dowd KA, Beth Post C, Pierson TC. Virology 479-480 508-517 (2015)
  7. The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Heinz FX, Stiasny K. Microbiol. Mol. Biol. Rev. 81 (2017)
  8. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. Rey FA, Stiasny K, Vaney MC, Dellarole M, Heinz FX. EMBO Rep. 19 206-224 (2018)
  9. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. Shukla R, Ramasamy V, Shanmugam RK, Ahuja R, Khanna N. Front Cell Infect Microbiol 10 572681 (2020)
  10. Immune Response to Dengue and Zika. Ngono AE, Shresta S. Annu. Rev. Immunol. 36 279-308 (2018)
  11. Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens. Liljeroos L, Malito E, Ferlenghi I, Bottomley MJ. J Immunol Res 2015 156241 (2015)
  12. The role of Fc receptors in HIV prevention and therapy. Boesch AW, Brown EP, Ackerman ME. Immunol. Rev. 268 296-310 (2015)
  13. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development. Acosta EG, Bartenschlager R. Expert Rev Vaccines 15 467-482 (2016)
  14. Molecular basis of antibody-mediated neutralization and protection against flavivirus. Dai L, Wang Q, Qi J, Shi Y, Yan J, Gao GF. IUBMB Life 68 783-791 (2016)
  15. Zika Virus Structure, Maturation, and Receptors. Sirohi D, Kuhn RJ. J. Infect. Dis. 216 S935-S944 (2017)
  16. Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. VanBlargan LA, Goo L, Pierson TC. Microbiol. Mol. Biol. Rev. 80 989-1010 (2016)
  17. Immune correlates for dengue vaccine development. Srikiatkhachorn A, Yoon IK. Expert Rev Vaccines 15 455-465 (2016)
  18. Recent advances in understanding dengue. Yacoub S, Mongkolsapaya J, Screaton G. F1000Res 5 (2016)
  19. Cryo-EM Studies of Virus-Antibody Immune Complexes. Li N, Li Z, Fu Y, Cao S. Virol Sin 35 1-13 (2020)
  20. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. Khandia R, Munjal A, Dhama K, Karthik K, Tiwari R, Malik YS, Singh RK, Chaicumpa W. Front Immunol 9 597 (2018)
  21. The mechanistic role of antibodies to dengue virus in protection and disease pathogenesis. Gan ES, Ting DH, Chan KR. Expert Rev Anti Infect Ther 15 111-119 (2017)
  22. Cross-Reactive Immunity Among Flaviviruses. Rathore APS, St John AL. Front Immunol 11 334 (2020)
  23. Molecular Insights into the Flavivirus Replication Complex. van den Elsen K, Quek JP, Luo D. Viruses 13 956 (2021)
  24. Structures and Functions of the Envelope Glycoprotein in Flavivirus Infections. Zhang X, Jia R, Shen H, Wang M, Yin Z, Cheng A. Viruses 9 (2017)
  25. The immune response against flaviviruses. Slon Campos JL, Mongkolsapaya J, Screaton GR. Nat. Immunol. 19 1189-1198 (2018)
  26. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine. Screaton G, Mongkolsapaya J. Cold Spring Harb Perspect Biol 10 (2018)
  27. Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development. Tsai WY, Lin HE, Wang WK. Front Microbiol 8 1372 (2017)
  28. Dengue: an update on treatment options. Chan CY, Ooi EE. Future Microbiol 10 2017-2031 (2015)
  29. Development of Antibody Therapeutics against Flaviviruses. Sun H, Chen Q, Lai H. Int J Mol Sci 19 (2017)
  30. Inhibitory Antibodies Targeting Emerging Viruses: Advancements and Mechanisms. Jin J, Simmons G. Clin. Vaccine Immunol. 23 535-539 (2016)
  31. The Development of Peptide-based Antimicrobial Agents against Dengue Virus. Huang YW, Lee CT, Wang TC, Kao YC, Yang CH, Lin YM, Huang KS. Curr. Protein Pept. Sci. 19 998-1010 (2018)
  32. A comprehensive review on staphylococcal protein A (SpA): Its production and applications. Rigi G, Ghaedmohammadi S, Ahmadian G. Biotechnol Appl Biochem 66 454-464 (2019)
  33. Current status and perspectives on vaccine development against dengue virus infection. Park J, Kim J, Jang YS. J Microbiol 60 247-254 (2022)
  34. Dengue virus infection - a review of pathogenesis, vaccines, diagnosis and therapy. Kok BH, Lim HT, Lim CP, Lai NS, Leow CY, Leow CH. Virus Res 324 199018 (2023)
  35. Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era? Galula JU, Salem GM, Chang GJ, Chao DY. Hum Vaccin Immunother 15 2328-2336 (2019)
  36. Flavivirus: From Structure to Therapeutics Development. Zhao R, Wang M, Cao J, Shen J, Zhou X, Wang D, Cao J. Life (Basel) 11 615 (2021)
  37. Protection against dengue virus requires a sustained balance of antibody and T cell responses. Valentine KM, Croft M, Shresta S. Curr Opin Virol 43 22-27 (2020)
  38. Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design? Wilken L, Rimmelzwaan GF. Pathogens 9 (2020)
  39. Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS. Joseph J, Sandel G, Kulkarni R, Alatrash R, Herrera BB, Jain P. Pathogens 13 14 (2023)
  40. Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus. Jin J, Simmons G. Viruses 11 (2019)
  41. Considering Genomic and Immunological Correlates of Protection for a Dengue Intervention. Blight J, Alves E, Reyes-Sandoval A. Vaccines (Basel) 7 (2019)
  42. Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement. Sarker A, Dhama N, Gupta RD. Front Immunol 14 1200195 (2023)
  43. Discovery of B-cell epitopes for development of dengue vaccines and antibody therapeutics. Anasir MI, Poh CL. Med Microbiol Immunol 211 1-18 (2022)
  44. Landscape of Monoclonal Antibodies Targeting Zika and Dengue: Therapeutic Solutions and Critical Insights for Vaccine Development. Dussupt V, Modjarrad K, Krebs SJ. Front Immunol 11 621043 (2020)
  45. Microbiology catches the cryo-EM bug. Earl LA, Falconieri V, Subramaniam S. Curr. Opin. Microbiol. 43 199-207 (2018)
  46. Morphological Diversity and Dynamics of Dengue Virus Affecting Antigenicity. Fibriansah G, Lim XN, Lok SM. Viruses 13 1446 (2021)
  47. Naïve Human Antibody Libraries for Infectious Diseases. Chan SK, Rahumatullah A, Lai JY, Lim TS. Adv Exp Med Biol 1053 35-59 (2017)
  48. The Many Faces of a Dynamic Virion: Implications of Viral Breathing on Flavivirus Biology and Immunogenicity. Dowd KA, Pierson TC. Annu Rev Virol 5 185-207 (2018)
  49. Viral-Induced Enhanced Disease Illness. Smatti MK, Al Thani AA, Yassine HM. Front Microbiol 9 2991 (2018)

Articles citing this publication (74)